Skip to main content
●+254 119 023975 support@dnalabskenya.com
Patient Portal LoginB2B / Doctor Portal
DNA LabsKenya
Medical information Clinical review pending

Genetic Testing

ARSA Gene Metachromatic Leukodystrophy Genetic Test

Genetic test using Next Generation Sequencing (NGS) to detect mutations in the ARSA gene, associated with Metachromatic Leukodystrophy (MLD), a serious metabolic disorder affecting the nervous system. Early diagnosis is key.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube) or extracted DNA. Confirm specific requirements with the laboratory before booking.
Results
Confirm with the laboratory before booking.
Preparation
No special preparation is typically required for a blood draw. Confirm with the laboratory before booking.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the ARSA Gene Metachromatic Leukodystrophy Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

WhatsApp the claims team Call us
01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals with a family history of Metachromatic Leukodystrophy (MLD).
  • ✓Individuals experiencing symptoms suggestive of MLD, such as motor difficulties, cognitive decline, or behavioral changes.
  • ✓Patients undergoing genetic counseling for hereditary neurological conditions.
  • ✓Carrier screening for individuals with a family history of MLD.
02

In plain language

What this test helps you understand

This test identifies mutations in the ARSA gene, which are responsible for Metachromatic Leukodystrophy (MLD). It helps in diagnosing MLD, understanding genetic risk, and informing family planning decisions.
The ARSA Gene Metachromatic Leukodystrophy NGS Genetic DNA Test is a specialized genetic test designed to identify mutations in the ARSA gene. These mutations are the cause of Metachromatic Leukodystrophy (MLD), a serious metabolic disorder that affects the nervous system and can lead to progressive neurological decline. Early detection through genetic testing is crucial for effective management and potential treatment options. This test utilizes Next Generation Sequencing (NGS) technology to detect specific mutations in the ARSA gene by analyzing DNA from a blood sample or extracted DNA. Understanding your genetic predisposition to MLD can help in family planning and accessing specialized care.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is typically required for a blood draw. Confirm with the laboratory before booking.
SampleBlood sample (EDTA tube) or extracted DNA. Confirm specific requirements with the laboratory before booking.
MethodologyNext Generation Sequencing (NGS) of the ARSA gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects mutations in the ARSA gene but may not identify all possible mutations. A negative result does not completely rule out MLD if clinical suspicion is high. Results should be interpreted in conjunction with clinical findings and family history.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

MLD is a rare, inherited metabolic disorder that affects the nervous system. It is caused by a deficiency of the enzyme arylsulfatase A (ARSA), leading to the buildup of fatty substances in the brain and nerves.
Testing is recommended for individuals with symptoms suggestive of MLD, those with a family history of the disorder, and for carrier screening purposes in affected families.
The test involves analyzing a sample of your DNA (usually from a blood sample) to look for specific changes (mutations) in the ARSA gene.
NGS technology is highly accurate for detecting known mutations in the ARSA gene. However, it may not detect all possible rare mutations. Discuss the test's limitations with your doctor.
It is essential to discuss your results with a healthcare professional or genetic counselor. They can help you understand the implications and discuss potential next steps, including management options or further testing if needed.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →

Beta CTx Beta Crosslaps Collagen Type 1 C-Telopeptide Test

The Beta CTx test measures bone resorption markers to help assess bone health and osteoporosis risk.

Learn more →

Bcell Rearrangement Detection Test

The Bcell Rearrangement Detection Test helps diagnose leukemia by identifying genetic changes in B cells. It's a key tool for hematologists and oncologists.

Learn more →

Dpd Gene Mutations 5Fu Toxicity Detection Test

This genetic test identifies mutations in the DPD gene, helping predict the risk of severe side effects from the chemotherapy drug 5-fluorouracil (5FU).

Learn more →

Ganciclovir Resistance Detection Test

This test checks for genetic changes in the cytomegalovirus (CMV) that may make it resistant to the antiviral medication Ganciclovir. It helps guide treatment decisions, especially for patients with weakened immune systems.

Learn more →
Chat on WhatsApp